Gilead and PAHO Expand HIV Drug Access
Gilead Sciences and PAHO agreed to widen access to the HIV prevention drug lenacapavir across Latin America and the Caribbean. The deal provides a procurement pathway for fourteen countries not covered by generic licensing agreements.
Xurve View
Insights:
Xurve View
Gilead Sciences Inc. will supply its twice-yearly HIV prevention drug through the Pan American Health Organization's purchasing system, targeting 14 countries in Latin America and the Caribbean. New HIV infections across the region rose 13% between 2010 and 2024, driven by gaps in prevention medicine utilization. The agreement establishes a direct procurement pathway for nations excluded from previous generic licensing deals.
